Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Together these results indicate that NRARP plays a dual role in T-ALL pathogenesis, regulating both Notch and Wnt pathways, with opposite functional effects depending on Notch activity.
|
31586130 |
2020 |
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
This study attempted to investigate the expression of NRARP in thyroid cancer tissues and assess the influence of NRARP on cell proliferation, apoptosis, cell cycle, and invasion in thyroid cancer.
|
27364790 |
2016 |
Thyroid carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
This study attempted to investigate the expression of NRARP in thyroid cancer tissues and assess the influence of NRARP on cell proliferation, apoptosis, cell cycle, and invasion in thyroid cancer.
|
27364790 |
2016 |
Malignant neoplasm of thyroid
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study attempted to investigate the expression of NRARP in thyroid cancer tissues and assess the influence of NRARP on cell proliferation, apoptosis, cell cycle, and invasion in thyroid cancer.
|
27364790 |
2016 |
Thyroid Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study attempted to investigate the expression of NRARP in thyroid cancer tissues and assess the influence of NRARP on cell proliferation, apoptosis, cell cycle, and invasion in thyroid cancer.
|
27364790 |
2016 |
Papillary thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, these results indicate that NRARP is an important clinical biomarker in thyroid carcinoma and it promotes EMT induction as well as the progression of PTCs via NOTCH signaling activation.
|
28207739 |
2017 |
Thyroid carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Therefore, these results indicate that NRARP is an important clinical biomarker in thyroid carcinoma and it promotes EMT induction as well as the progression of PTCs via NOTCH signaling activation.
|
28207739 |
2017 |
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The role of NRARP in carcinogenesis deserves extensive investigations.
|
27364790 |
2016 |
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The results revealed that NRARP expression was significantly associated with tumor differentiation (P=0.001), Tumor-Node-Metastasis stage (P=0.004) and cigarette smoking (P<i><</i>0.001).
|
30008880 |
2018 |
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
NOTCH signaling and its downstream NOTCH-Regulated Ankyrin Repeat Protein (NRARP) have been implicated in oncogenesis of many cancers, but the roles in PTCs are less studied.
|
28207739 |
2017 |
Brain Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Malignant neoplasm of brain
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Benign neoplasm of brain, unspecified
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Brain Tumor, Primary
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Recurrent Brain Neoplasm
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Primary malignant neoplasm of brain
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Neoplasms, Intracranial
|
0.300 |
Biomarker
|
group |
CTD_human |
Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.
|
21127729 |
2010 |
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In summary, the present study demonstrated that NRARP protein is overexpressed in NSCLC and that high NRARP expression is correlated with tumor progression and overall survival time.
|
30008880 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In summary, the present study demonstrated that NRARP protein is overexpressed in NSCLC and that high NRARP expression is correlated with tumor progression and overall survival time.
|
30008880 |
2018 |
Infectious Otitis Media
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, genes encoding Notch receptors and ligands (Notch1, Notch2, Notch3, Notch4 and Dll1) and the Notch target genes (Hes1, Hes5, Hey1, NRARP) in AOM decreased significantly.
|
28676722 |
2017 |
leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Importantly, mice transplanted with T-cells overexpressing NRARP alone developed leukemia with similar kinetics to those transplanted with T-NOTCH1 cells.
|
31586130 |
2020 |
Childhood Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Importantly, mice transplanted with T-cells overexpressing NRARP alone developed leukemia with similar kinetics to those transplanted with T-NOTCH1 cells.
|
31586130 |
2020 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, we showed that NRARP inhibited the growth of Notch-dependent T cell acute lymphoblastic leukemia (T-ALL) cell lines and bound directly to the core Notch transcriptional activation complex (NTC), requiring both the transcription factor RBPJ and the Notch intracellular domain (NICD), but not Mastermind-like proteins or DNA.
|
31690634 |
2019 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Notch-regulated ankyrin-repeat protein (NRARP) has recently been reported to be involved in a number of malignant cancers; however, its role in non-small lung cancer (NSCLC) remains unclear.
|
30008880 |
2018 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Notch-regulated ankyrin-repeat protein (NRARP) has recently been reported to be involved in a number of malignant cancers; however, its role in non-small lung cancer (NSCLC) remains unclear.
|
30008880 |
2018 |